News Center

Discover all of the trending news of the Ipsen Group

12 results

Financial information

Ipsen – 2019 First Quarter results – April 24, 2019

To register for the webcast, please Click here.


Ipsen completes acquisition of Clementia Pharmaceuticals

Today, Ipsen announced the closing of the acquisition of Clementia Pharmaceuticals. A Canadian clinical-stage biotech…

Event Oncology

Ipsen is present at ESGE Days with an educational symposium and two oral presentations

ESGE DAYS 2019 is the second edition of a congress dedicated to increasing quality of…


Building the market access ecosystem

At Eyeforpharma 2019, Ipsen’s Senior VP Market Access, Ulf Staginnus is participating in a…

CSR People

Ipsen champions women in leadership and gender equality this International Women’s Day!

International Women’s Day is a great opportunity to celebrate our extraordinary female colleagues around the…


Ipsen acquisition of Clementia Pharmaceuticals – Conference

Ipsen will host a conference call and web conference today to discuss this announcement. Participants…

Financial information

Ipsen reiterated its commitment to the Innobio-2 fund

On February 4, 2019, Ipsen was delighted to attend the presentation of the new CSF…


Ipsen commits to making all its published scientific research freely accessible to everyone

We aim to publish the results of our clinical studies in peer-reviewed medical and scientific…


Ipsen announces 50 posters to be presented at the 2019 TOXINS Congress – January 16-19

TOXINS is a key conference for thought leaders – clinicians and researchers from academia and…


Ipsen: a story of transformation and growth

On December 12th, at the closing ceremony of the prestigious French Finance congress, Financium, Aymeric Le Chatelier,…

Group People

Ipsen Seasons greetings

​A New Year has come​ and it's a wonderful time to reflect on what matters…

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2020